medgenМедицинская генетикаMedical Genetics2073-7998Publishing House «Genius Media» LLCmedgen-243Research ArticleНАУЧНЫЕ ОБЗОРЫREVIEWРоль вовлеченных в иммунный ответ и воспаление генов в патогенезе рака яичников (обзорная статья)Role of genes involved in immune response and inflammation and the pathogenesis of ovarian cancerМингажеваЭ. Т.MingajevaE. T.Elvira.F91@mail.ruПрокофьеваД. С.ProkofyevaD. S.noemail@neicon.ruСакаеваД. Д.SakaevaD. D.noemail@neicon.ruФаисхановаР. Р.FaishanovaR. R.noemail@neicon.ruХуснутдиноваЭ. К.KhusnutdinovaE. K.noemail@neicon.ruБашкирский государственный университетРоссияBashkir State UniversityRussian FederationГБУЗ Республиканский клинический онкологический диспансерРоссияRepublic Clinical Oncology CenterRussian FederationБашкирский государственный университет; Институт биохимии и генетики Уфимского научного центра РАНРоссияBashkir State University; Institute of Biochemistry and GeneticsRussian Federation201719092017163311Copyright © Мингажева Э.Т., Прокофьева Д.С., Сакаева Д.Д., Фаисханова Р.Р., Хуснутдинова Э.К., 20172017Мингажева Э.Т., Прокофьева Д.С., Сакаева Д.Д., Фаисханова Р.Р., Хуснутдинова Э.К.Mingajeva E.T., Prokofyeva D.S., Sakaeva D.D., Faishanova R.R., Khusnutdinova E.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medgen-journal.ru/jour/article/view/243

Рак яичников (РЯ) занимает одно из лидирующих мест по смертности среди онкологических заболеваний репродуктивной сферы у женщин. Одним из важных факторов риска РЯ выступает генетическая предрасположенность. В последнее время при исследовании патогенеза злокачественных новообразований яичников особое внимание уделяется роли иммунной системы. В данном обзоре представлен анализ отечественной и зарубежной литературы, посвященной изучению роли провоспалительных цитокинов, обеспечивающих мобилизацию воспалительного ответа, противовоспалительных цитокинов, ограничивающих развитие воспаления, транскрипционных факторов и других участников иммунного ответа в канцерогенезе яичников.

Ovarian cancer (OC) is one of the leading factor in mortality among the cancers of the female reproductive system. One of the important risk factors for ovarian cancer acts is a genetic predisposition. Recently in the study of the malignant neoplasms pathogenesis of ovary special attention was paid to the role of the immune system. This review presents the analysis of domestic and foreign literature devoted to the role of proinflammatory cytokines that mobilize inflammatory response, inflammatory cytokines limiting the development of inflammation, the transcription factors and other participants of the immune response in the ovarian carcinogenesis.

рак яичниковиммунная системаядерный транскрипционный фактор NF-kBцитокиныциклооксигеназыхемокиныovarian cancerimmune systemnuclear factor NF-kBcytokinescyclooxygenaseschemokinesReferencesGLOBOCAN 2012. Cancer Incidence, Mortality and Prevalence Worldwide [Электронный ресурс] URL: http://globocan.iarc.fr. (дата обращения: 5.10.2016).GLOBOCAN 2012. Cancer Incidence, Mortality and Prevalence Worldwide [Электронный ресурс] URL: http://globocan.iarc.fr. (дата обращения: 5.10.2016).Charbonneau B, Goode EL, Kalli KR, et al. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013; 33(2): 137-64.Charbonneau B, Goode EL, Kalli KR, et al. The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 2013; 33(2): 137-64.Воробьева ЛИ, Свинцицкий ВС, Ткаля ЮГ. Гормональный канцерогенез и обоснование применения гормональной терапии в лечении больных раком яичника (обзор литературы). Онкогинекология. 2013; 1(9).Воробьева ЛИ, Свинцицкий ВС, Ткаля ЮГ. Гормональный канцерогенез и обоснование применения гормональной терапии в лечении больных раком яичника (обзор литературы). Онкогинекология. 2013; 1(9).Аксель ЕМ. Статистика злокачественных новообразований женских половых органов. Онкогинекология. 2012; (1): 9-17.Аксель ЕМ. Статистика злокачественных новообразований женских половых органов. Онкогинекология. 2012; (1): 9-17.Каприн АД, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена. Филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России. 2015. 250 с.Каприн АД, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена. Филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России. 2015. 250 с.O’Donovan, P., Livingston D. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010. 31, 961-967.O’Donovan, P., Livingston D. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010. 31, 961-967.Balmana J., Diez O., Castiglione M. ESMO Guidelines Working Group. BRCA in breast cancer: ESMO clinical recommendations. Annals of Oncology. 2009; 20: 19-20.Balmana J., Diez O., Castiglione M. ESMO Guidelines Working Group. BRCA in breast cancer: ESMO clinical recommendations. Annals of Oncology. 2009; 20: 19-20.Zeineldin R., Muller C.Y., Stack M.S., Hudson L.G. 2010. Targeting the EGF receptor for ovarian cancer therapy. J. Oncol., 2010; 2010: 414676.Zeineldin R., Muller C.Y., Stack M.S., Hudson L.G. 2010. Targeting the EGF receptor for ovarian cancer therapy. J. Oncol., 2010; 2010: 414676.Singh M, Loftus T, Webb E, Benencia F Minireview: Regulatory T Cells and Ovarian Cancer. Immunol Invest. 2016 Nov; 45(8): 712-720.Singh M, Loftus T, Webb E, Benencia F Minireview: Regulatory T Cells and Ovarian Cancer. Immunol Invest. 2016 Nov; 45(8): 712-720.Auer K, Bachmayr-Heyda A, Sukhbaatar N. et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget. 2016 Sep 20; 7(38): 61336-61354.Auer K, Bachmayr-Heyda A, Sukhbaatar N. et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget. 2016 Sep 20; 7(38): 61336-61354.Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem. 2004; 382: 393-409.Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem. 2004; 382: 393-409.Philip, M., Rowley, D.A., Schreiber, H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004; 14(6): 433-9.Philip, M., Rowley, D.A., Schreiber, H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004; 14(6): 433-9.Samarasinghe B. The Hallmarks of Cancer 8: Tumor-Promoting Inflammation. Scientific American. 2014. [электронный ресурс] URL: http:.blogs.scientificamerican.com. (дата обращения: 13.09.15).Samarasinghe B. The Hallmarks of Cancer 8: Tumor-Promoting Inflammation. Scientific American. 2014. [электронный ресурс] URL: http:.blogs.scientificamerican.com. (дата обращения: 13.09.15).Guo RX, Qiao YH, Zhou Y, et al. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int. 2008; (58): 749-756.Guo RX, Qiao YH, Zhou Y, et al. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int. 2008; (58): 749-756.Plewka D, Kowalczyk AE, Jakubiec-Bartnik B, et al. Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors. Folia Histochem Cytobiol. 2014; 52(2): 124-37.Plewka D, Kowalczyk AE, Jakubiec-Bartnik B, et al. Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors. Folia Histochem Cytobiol. 2014; 52(2): 124-37.Heron E, Deloukas P, van Loon AP. The complete exon intron structure of the 156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal transduction. Genomics. 1995; (30): 493-505.Heron E, Deloukas P, van Loon AP. The complete exon intron structure of the 156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal transduction. Genomics. 1995; (30): 493-505.Luo YQ, Wang D, Gong T, Zhu. An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility. Oncotarget. 2016; 7936): 58659-58670.Luo YQ, Wang D, Gong T, Zhu. An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility. Oncotarget. 2016; 7936): 58659-58670.Lu ZH, Gu XJ, Shi KZ, et al. Association between genetic polymorphisms of inflammatory response genes and the risk of ovarian cancer. J Formos Med Assoc. 2016; 115(1): 31-7.Lu ZH, Gu XJ, Shi KZ, et al. Association between genetic polymorphisms of inflammatory response genes and the risk of ovarian cancer. J Formos Med Assoc. 2016; 115(1): 31-7.Wang D, Xie T, Xu J, et al. Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies. Sci Rep. 2016 22; 6: 30220.Wang D, Xie T, Xu J, et al. Genetic association between NFKB1 -94 ins/del ATTG Promoter Polymorphism and cancer risk: a meta-analysis of 42 case-control studies. Sci Rep. 2016 22; 6: 30220.Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11: 293-299.Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11: 293-299.http: //www.ncbi.nlm.nih.gov/gene/3091http: //www.ncbi.nlm.nih.gov/gene/3091Jin Y, Wang H, Liang X et al. Pathological and prognostic significance of hypoxia-inducible factor 1a expression inepithelial ovarian cancer: a meta-analysis. Tumour Biol. 2014; 35(8): 8149-59.Jin Y, Wang H, Liang X et al. Pathological and prognostic significance of hypoxia-inducible factor 1a expression inepithelial ovarian cancer: a meta-analysis. Tumour Biol. 2014; 35(8): 8149-59.Ricciardolo FL, Sterk PJ, Gaston B et al. Nitric oxide in health and disease of the respiratory system. Physiol. Rev.2004; 84: 731-765.Ricciardolo FL, Sterk PJ, Gaston B et al. Nitric oxide in health and disease of the respiratory system. Physiol. Rev.2004; 84: 731-765.Wink DA, Vodovotz Y, Laval J. et al. The multifaceted roles of nitric oxide. Carcinagenes. 1998; 19(5): 711-721.Wink DA, Vodovotz Y, Laval J. et al. The multifaceted roles of nitric oxide. Carcinagenes. 1998; 19(5): 711-721.Smith W.L, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000; 69: 145-182.Smith W.L, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000; 69: 145-182.Kosaka T, Miyata A, Ihara H. et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem.1994; (221): 889-97.Kosaka T, Miyata A, Ihara H. et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem.1994; (221): 889-97.Lurie G, Terry KL, Wilkens LR, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010; (21): 1731-1741.Lurie G, Terry KL, Wilkens LR, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010; (21): 1731-1741.Мордвинов ВА, Фурман ДП. Цитокины: биологические свойства и регуляция экспрессии гена интерлейкина-5 человека. Вавиловский журнал генетики и селекции.2009; 13(1): 53-67.Мордвинов ВА, Фурман ДП. Цитокины: биологические свойства и регуляция экспрессии гена интерлейкина-5 человека. Вавиловский журнал генетики и селекции.2009; 13(1): 53-67.Lippitz BE, Harris RA. Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016 11; 5(5): e1093722.Lippitz BE, Harris RA. Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016 11; 5(5): e1093722.Kim S, Gwak H, Kim HS, et al. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membranebound IL-6R in vitro. Oncotarget. 2016Dec 13; 7(50): 83148 -83159.Kim S, Gwak H, Kim HS, et al. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membranebound IL-6R in vitro. Oncotarget. 2016Dec 13; 7(50): 83148 -83159.Browne A, Sriraksa R, Guney T, et al. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine 2013; 64(1): 413-21.Browne A, Sriraksa R, Guney T, et al. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine 2013; 64(1): 413-21.Koensgen D, Bruennert D, Ungureanu S, et al. Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine. 2015; 71(2): 334-8.Koensgen D, Bruennert D, Ungureanu S, et al. Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine. 2015; 71(2): 334-8.Stronach EA, Cunnea P, Turner C,et al. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovariancarcinoma. Oncotarget. 2015 Oct 13; 6(31): 31593-603.Stronach EA, Cunnea P, Turner C,et al. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovariancarcinoma. Oncotarget. 2015 Oct 13; 6(31): 31593-603.Park MS, Kim BR, Kang S, Kim DY, Rho SB.The antihypertension drug doxazosin suppresses JAK/STATs phosphorylation and enhances the effects of IFN-a/g-induced apoptosis.Genes Cancer. 2014 Nov; 5(11-12): 470-9.Park MS, Kim BR, Kang S, Kim DY, Rho SB.The antihypertension drug doxazosin suppresses JAK/STATs phosphorylation and enhances the effects of IFN-a/g-induced apoptosis.Genes Cancer. 2014 Nov; 5(11-12): 470-9.Johnson CL, Green DS, Zoon KC. Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin. J Interferon Cytokine Res. 2015; 35: 55-62.Johnson CL, Green DS, Zoon KC. Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin. J Interferon Cytokine Res. 2015; 35: 55-62.Green DS, Nunes AT, Annunziata CM, Zoon KC.Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine Growth Factor Rev. 2016 Jun; 29: 109-15Green DS, Nunes AT, Annunziata CM, Zoon KC.Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine Growth Factor Rev. 2016 Jun; 29: 109-15Goshima F, Esaki S, Luo C, Kamakura M, Kimura H, Nishiyama Y. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant andgranulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int J Cancer. 2014 Jun 15; 134(12): 2865-77.Goshima F, Esaki S, Luo C, Kamakura M, Kimura H, Nishiyama Y. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant andgranulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int J Cancer. 2014 Jun 15; 134(12): 2865-77.Liao JB, Swensen RE, Ovenell KJ, et al. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046-X.Liao JB, Swensen RE, Ovenell KJ, et al. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046-X.Woolery KT, Kruk PA. Ovarian Epithelial-Stromal Interactions: Role of Interleukins 1 and 6. Obstetrics and Gynecology International 01/2011; 2011: 358493.Woolery KT, Kruk PA. Ovarian Epithelial-Stromal Interactions: Role of Interleukins 1 and 6. Obstetrics and Gynecology International 01/2011; 2011: 358493.Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19 (2): 382-4.Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics 1994; 19 (2): 382-4.Тотолян АА, Фрейдлин ИС. Клетки иммунной системы. CПб: Наука, 2000: 231 с.Тотолян АА, Фрейдлин ИС. Клетки иммунной системы. CПб: Наука, 2000: 231 с.Stylianou E, Saklatvala J. Interleukin-1.m International Journal of Biochemistry and Cell Biology. 1998; 30(10): 1075-1079.Stylianou E, Saklatvala J. Interleukin-1.m International Journal of Biochemistry and Cell Biology. 1998; 30(10): 1075-1079.Charles A. Dinarello in The Cytokine Handbook / Ed. A.A. Thomson. London: Academic Press, 2003. 643-668.Charles A. Dinarello in The Cytokine Handbook / Ed. A.A. Thomson. London: Academic Press, 2003. 643-668.Streicher KL. Activation of a nuclear factor kappaB / interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells / K.L. Streicher, N.E. Willmarth, J. Garcia et al. Mol. Cancer Res. 2007; 5(8): 847-861.Streicher KL. Activation of a nuclear factor kappaB / interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells / K.L. Streicher, N.E. Willmarth, J. Garcia et al. Mol. Cancer Res. 2007; 5(8): 847-861.Apte RN, Krelin Y, Song X, et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 2006; 42: 751-759.Apte RN, Krelin Y, Song X, et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 2006; 42: 751-759.White KL, Schildkraut JM, Palmieri RT, et al. Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants. Cancer Res. 2012; 72: 1064-1069.White KL, Schildkraut JM, Palmieri RT, et al. Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants. Cancer Res. 2012; 72: 1064-1069.Triozzi P.L, Aldrich W, Singh A. Effects of Interleukin-1 Receptor Antagonist on Tumor Stroma in Experimental Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2011; 52: 5529 - 5535.Triozzi P.L, Aldrich W, Singh A. Effects of Interleukin-1 Receptor Antagonist on Tumor Stroma in Experimental Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2011; 52: 5529 - 5535.Mustea A., Pirvulescu C., Konsgen D. et al. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008; 42(1): 77-84.Mustea A., Pirvulescu C., Konsgen D. et al. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008; 42(1): 77-84.Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-1725.Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-1725.Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11(9): 372-7.Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11(9): 372-7.Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999; 19: 350-364.Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol 1999; 19: 350-364.Devin A, Cook A, Lin Y et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000; 12: 419-429.Devin A, Cook A, Lin Y et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity 2000; 12: 419-429.van Horssen R, Rens JA, Schipper D, et al. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization. Apoptosis. 2006; 11(12): 2137-45.van Horssen R, Rens JA, Schipper D, et al. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization. Apoptosis. 2006; 11(12): 2137-45.Johnston DA. TNF induction of jagged-1 in endothelial cells is NF kappa B-dependent Gene. 2009; 435: 36-44.Johnston DA. TNF induction of jagged-1 in endothelial cells is NF kappa B-dependent Gene. 2009; 435: 36-44.Block MS, Maurer MJ, Goergen K, et al. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 2015; 73(1): 108-13.Block MS, Maurer MJ, Goergen K, et al. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 2015; 73(1): 108-13.Kolomeyevskaya N, Eng KH, Khan AN, et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-a and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138(2): 352-7.Kolomeyevskaya N, Eng KH, Khan AN, et al. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-a and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015; 138(2): 352-7.Gleizes PE., Munger JS., Nunes I. et al. TGF-beta latency: biological significance and mechanisms of activation. Stem. Cells. 1997; 15 (3): 190-197.Gleizes PE., Munger JS., Nunes I. et al. TGF-beta latency: biological significance and mechanisms of activation. Stem. Cells. 1997; 15 (3): 190-197.Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001; 29: 117-129.Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001; 29: 117-129.Datto MB., Hu PP., Kowalik TF. et al. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/ WAF1/Cip1 and p15/INK4B. Mol. Cell. Biol. 1997; 17: 2030-2037.Datto MB., Hu PP., Kowalik TF. et al. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/ WAF1/Cip1 and p15/INK4B. Mol. Cell. Biol. 1997; 17: 2030-2037.Gao J, Zhu Y, Nilsson M, Sundfeldt K. TGF b isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int. 2014; 14(1): 72.Gao J, Zhu Y, Nilsson M, Sundfeldt K. TGF b isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int. 2014; 14(1): 72.

The authors declare that there are no conflicts of interest present.